State Street Corp Janux Therapeutics, Inc. Transaction History

State Street Corp

$2.21 Trillion
Q1 2024

A detailed history of State Street Corp transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 399,467 shares of JANX stock, worth $16.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

399,467

Previous 347,585 14.93%

Holding current value

$16.7 Million

Previous $3.73 Million 303.3%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$7.93 - $49.75 $411,424 - $2.58 Million	51,882 Added 14.93%	399,467 $15 Million
Q4 2023 Feb 14, 2024	BUY	$5.85 - $11.7 $93,681 - $187,363	16,014 Added 4.83%	347,585 $3.73 Million
Q3 2023 Nov 14, 2023	SELL	$9.56 - $14.0 $9,741 - $14,266	-1,019 Reduced 0.31%	331,571 $3.34 Million
Q2 2023 Aug 14, 2023	BUY	$11.08 - $15.92 $376,287 - $540,659	33,961 Added 11.37%	332,590 $3.95 Million
Q1 2023 May 15, 2023	BUY	$11.25 - $22.21 $174,588 - $344,676	15,519 Added 5.48%	298,629 $3.61 Million

Q4 2022 Feb 14, 2023	BUY	$11.1 - $18.26 $209,823 - $345,168	18,903 Added 7.15%	283,110 $3.73 Million
Q3 2022 Nov 15, 2022	BUY	$10.82 - $16.84 $2,001 - $3,115	185 Added 0.07%	264,207 $3.58 Million
Q2 2022 Aug 15, 2022	BUY	$9.52 - $15.65 $209,668 - $344,675	22,024 Added 9.1%	264,022 $3.22 Million
Q1 2022 May 16, 2022	BUY	$13.24 - $20.24 $402,919 - $615,943	30,432 Added 14.38%	241,998 $3.47 Million
Q4 2021 Feb 14, 2022	BUY	$15.44 - $27.32 $570,075 - $1.01 Million	36,922 Added 21.14%	211,566 $4.17 Million
Q3 2021 Nov 15, 2021	BUY	$20.7 - $34.69 $3.62 Million - $6.06 Million	174,644 New	174,644 $3.78 Million

Others Institutions Holding JANX

# of Institutions

123

Shares Held

25.3M

Call Options Held

92K

Put Options Held

161K

View Full List

About Janux Therapeutics, Inc.

Ticker JANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,663,000
Market Cap $1.75B
Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...

More about JANX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Janux Therapeutics, Inc. Transaction History